# INTERVIEW: Oxford Biodynamics Presenting in Washington Summit

- Link: https://www.directorstalkinterviews.com/interview-oxford-biodynamics-presenting-washington-summit/412755300
- Published: 2018-07-24T09:49:17+01:00
- Author: Giles Arbor

**Oxford Biodynamics Plc** (LON:OBD) CSO Dr Alexandre Akoulitchev talks to DirectorsTalk
about presenting its work in Washington at the Summit on Emerging Immunotherapies
for Hematologic Diseases. Alexandre describes for us the field of immunotherapies,
what it is that OBD brings to the field, its expertise in patient stratifications
in immunotherapies applications, explains how relevant the earlier studies are to
new immunotherpy applications and the advantages EpiSwitch technology been demonstrating
in its latest applications.

Oxford BioDynamics Plc is a biotechnology company focused on the discovery and development
of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company’s award-winning, proprietary technology platform, EpiSwitch™, aims to
accelerate the drug discovery and development process, improve the success rate 
of therapeutic product development and take advantage of the increasing importance
of personalised medicine. In particular, EpiSwitch™ can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally, the technology
provides significant insights into disease mechanisms for drug discovery and product
re‐positioning programmes, and enables the personalisation of therapeutics for patients
in the context of challenging pricing environments where improved clinical outcomes
are critical.

Share on: